Amgen开始对MariTide进行后期试验, MariTide是一种减肥药物,月度服用。 Amgen begins late-stage trials for MariTide, a weight loss drug aimed at monthly dosing.

Amgen已开始对其减重药物 " MariTide " 进行两次后期试验,目的是提供比目前每周注射次数少的剂量计划。 Amgen has started two late-stage trials for its weight loss drug, MariTide, aiming to offer a less frequent dosing schedule compared to current weekly injections. 该药物作为每月一次的治疗进行测试,并可能挑战诺沃·诺迪斯克和伊莱·莉莉的减肥药物等现有市场领袖。 The drug is being tested as a monthly treatment and could challenge existing market leaders like Novo Nordisk's and Eli Lilly's weight loss drugs. MariTide帮助病人在早期试验中损失了高达20%的体重。 MariTide helped patients lose up to 20% of their body weight in earlier trials. 这些试验将涉及大约4 500名患2型糖尿病或不患2型糖尿病的病人,衡量72周后体重下降情况。 The trials will involve around 4,500 patients with or without type 2 diabetes, measuring weight loss after 72 weeks.